A novel hair growth-enhancing formulation for the treatment of male pattern baldness (androgenic alopecia).
Fifty percent of Caucasian men and women beyond the age of 40 suffer from progressive androgenic alopecia, and while prevalence in Asian, Native American and African-American men is reduced, it is still considerable. The needs of this large market, in addition to those who suffer from chemotherapy-induced alopecia, are not met by current hair loss treatments.
To view a sample of laboratory test results data, including a comparison to commercially available products, download the paper below.
Treatment of male pattern baldness (androgenic alopecia).
Novel bioengineered peptide that regulates the Wnt/beta-catenin canonical pathway. Application of the peptide in a topical formulation results in substantially increased hair growth compared to other commercially available products.
For many people, this novel formulation could prove to be the only effective, affordable means of treating hair loss due to androgenic alopecia or chemotherapy.
Current treatments have limited efficacy. In studies, only 15% of patients actually regrow hair following treatment with other products. In direct comparisons, this technology is substantially more effective at accelerating hair growth.
Effective treatment for chemotherapy induced alopecia and improves bone-mineral metabolism.